Arian Lundberg

Arian Lundberg

Affiliated to Research
Visiting address: BioClinicum J 5:30 Visionsgatan 4, 17164 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Rodriguez-Wallberg, 171 77 Stockholm
Part of:

About me

  • I received my PhD degree from the Karolinska Institute, where my research focused on investigating the utility of transcriptional gene expression signatures to enhance therapy selection accuracy and improve outcomes for cancer patients.

    During my initial postdoctoral appointment at Stanford University in 2019, I conducted research in the field of personalized cancer medicine. Specifically, I explored "immune hot" cancer types such as Triple Negative Breast Cancer, Colorectal Cancer, and Melanoma, with the goal of advancing our understanding of these diseases and improving treatment strategies.

    Subsequently, in 2020, I joined the University of California, San Francisco, where I became an integral part of a laboratory that made significant contributions to the StandUp2 Cancer WCDT cohort. This cohort represents the largest gathering of patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States.

    Currently, I am based at the Institute of Cancer Research and Royal Marsden Hospital in London, UK, where I hold a senior postdoctoral scholar position within Prof. Johann de Bono's lab. Additionally, I serve as a researcher within the Rodriguez-Wallberg research team at the Karolinska Institute. My expertise encompasses bioinformatics, genomics, epigenetics, metagenomics, and cancer biomarker research.

Research

  • My primary research interest revolves around investigating the intricate 

  • interplay between genomic and epigenomic changes in cancer development and 
  • progression, with a specific focus on prostate cancer. To comprehensively 
  • explore this field, I utilize cutting-edge multi-omics approaches, such as 
  • Whole Genome Sequencing, RNA-seq, and Whole Genome Bisulfite Sequencing. Additionally, I incorporate ATAC-sequencing to gain valuable insights into the chromatin accessibility landscape. By conducting 
  • integrative research work in patients with prostate cancer, I aim to identify
    key molecular alterations that contribute to disease pathogenesis and 
  • ultimately pave the way for improved diagnostic and therapeutic strategies.

Articles

All other publications

Grants

  • Investigating the Association Between Microbiota Dysbiosis and Patient’s Survival in Advanced Prostate Cancer
    Helen Diller Family Comprehensive cancer center - Prostate Cancer Program Pilot Research Award - 2022
    1 July 2022 - 30 June 2023
  • Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
    Radiumhemmet research funds
    1 December 2015

Employments

  • Senior Postdoctoral fellow, Clinical studies and Cancer Biomarkers, Institute of Cancer Research, 2023-
  • Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2025
  • Postdoctoral Scholar, Bioinformatics - Genomics and epigenomics, University of California, San Francisco, 2020-2023
  • Postdoctoral Scholar, Bioinformatics - Molecular Biomarkers, Stanford University School of Medicine, 2019-2020

Degrees and Education

  • Doctor of Philosophy (PhD - Medical Bioinformatics), Medical bioinformatics, Transcriptional gene signatures: Passing the Restriction point for routine clinical implementation, Oncology and Pathology, Karolinska Institute, 2019
  • Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2019
  • Degree of Master of Science (Computational Biophysics and Biochemistry), Bioinformatics, Biochemistry and biophysics (DBB), Stockholm University, 2014
  • Master of Sciences (Bioinformatics), Bioinformatics, Limitation of algorithms for quantitative label-free LC-MS-based proteomics, Lund University, 2012

News from KI

Events from KI